Abstract:OBJECTIVE:To investigate the effects of lycopene on T lymphocyte subpopulations and pulmonary alveolar macrophagic (PAM) functions in rats with acute lung injury (ALI).METHODS:Rats were randomly divided into the following groups. (1) Control group, (2) ALI model group, (3) Low dose group,(4) Mid dose group and (5) High dose group. Control group and ALI model group were treated with solvent of lycopene, and the other groups were gastrically incubated with lycopene. Thirty-five days later, control group were given physiological saline, ALI model group and lycopene administrated groups were injected with lipopolysaccharide (LPS) (6.0 mg/kg) to induce ALI. One hour, four hours or six hours after LPS or physiological saline challenged, abdominal aorta blood for measuring lymphocyte subpopulations and bronchoalveolar lavage fluid for measuring function of PAM were gathered respectively.RESULTS:(1) At h 1, the percentages of CD3(+), CD4(+) and CD8(+) of lycopene administrated groups compared with control group were not significantly different. At h 4, the percentage of CD4(+) was similar to that at h 1. As for the percentages of CD3(+), except high dose group [(28.8+/-9.9)%] was significantly lower, low dose, mid dose and ALI model group showed no significant difference compared with control group[(39.5+/- 4.5)%]. The percentages of CD8(+) of ALI model and lycopene administrated rats, separately (10.2+/-3.9)%, (10.3+/-2.8)%, (9.8+/-2.8)%, (10.1+/-3.5)% , had been significantly reduced compared with control group[(15.1+/-2.5)%]; between ALI model and lycopene administrated groups there was no significant difference. The instance at h 6 was the same as that at h 4. The percentage ratios of CD4(+) T-lymphocyte to CD8(+) T-lymphocyte of ALI model rats were not significantly different compared with control group or lycopene administrated groups at h 1 and h 6. At h 4, the ratio of the CD4(+) and CD8(+) in Low dose and Mid dose groups had significant difference and ALI model, high dose hadn't when they were compared with control group. (2) Lycopene increased the phagocytic function of PAMs significantly at h 1(P<0.01), the optical density of PAM of control group, ALI model group, low dose group, mid dose group, high dose group was 0.136+/-0.025, 0.215+/-0.095, 0.239+/-0.052, 0.275+/-0.068 and 0.297+/-0.049; what happened at h 4 was similar to that at h 1; Phagocytic function of PAM of lycopene administrated groups was increased compared with control group. (3) The concentrations of tumor necrosis factor-alpha (TNF-alpha) in control group, ALI model group, low dose group, mid dose group, high dose groups were 1.50+/-0.30, 1.87+/-0.30, 1.76+/-0.40, 1.74+/- 0.38,1.62+/-0.35 microg/L;and those of IL-8 were 0.82+/-0.08, 0.99+/-0.14, 0.82+/-0.16, 0.84+/-0.16, 0.83+/-0.11 microg/L. The concentrations of TNF-alpha and interleukin-8 (IL-8) in BALF were decreased by lycopene, especially the levels of IL-8 were reduced significantly.CONCLUSION:Lycopene might attenuate lipopolysaccharide-induced impairment of lungs and improve ALI prognosis by increasing the phagocytic function of PAMs significantly and restraining the secretion of TNF-alpha and IL-8.

[Effects of Losartan on Pulmonary Dendritic Cells in Lipopolysaccharide- Induced Acute Lung Injury Mice].

Losartan Inhibits Conventional Dendritic Cell Maturation And Th1 And Th17 Polarization Responses: Novel Mechanisms Of Preventive Effects On Lipopolysaccharide-Induced Acute Lung Injury

Losartan Modulates T Helper Type 1 Cells and T Helper Type 17 Cells-Mediated Responses in a Mouse Model of Lipopolysaccharide-Induced Acute Lung Injury

Losartan, an Antagonist of AT1 Receptor for Angiotensin II, Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rat.

Losartan as a Reproposing Therapeutic Agent in Acute Respiratory Distress Syndrome: Modulating Inflammatory Responses and Cytokine Production

Valsartan attenuates LPS-induced ALI by modulating NF-κB and MAPK pathways

Losartan attenuates human monocyte-derived dendritic cell immune maturation via downregulation of lectin-like oxidized low-density lipoprotein receptor-1.

Effects of ambroxol on nuclear factor-kappa B signaling transduction in lipopolysaccaride-induced acute lung injury in rats

[Protective Effect of Synthetic Salidroside on Acute Lung Injury in Rats].

Plantamajoside Ameliorates Lipopolysaccharide-Induced Acute Lung Injury Via Suppressing NF-κB and MAPK Activation.

Effect of Losartan on Mechanical Ventilation-Induced Lung Injury in Diabetic Mice

Anti-inflammatory Effect of Losartan on LPS-induced Sepsis in Rats

[Angiotensin II type 2 receptor expression and its modulation in angiotensin II induced acute lung injury in rat].

Losartan inhibits LPS + ATP-induced IL-1beta secretion from mouse primary macrophages by suppressing NALP3 inflammasome.

Losartan Attenuates Ventilator-induced Lung Inj ury by Inhibiting NF-κB in Rats

Dihydroartemisinin Attenuates Lipopolysaccharide-Induced Acute Lung Injury In Mice By Suppressing Nf-Kappa B Signaling In An Nrf2-Dependent Manner

[Effect of Lycopene on Immunity in Rats with Acute Lung Injury].

Preventive Effect of Arctium lappa Polysaccharides on Acute Lung Injury through Anti-Inflammatory and Antioxidant Activities

Losartan, a Selective Antagonist of AT1 Receptor, Attenuates Acute Lung Injury Induced by Seawater Inhalation in Rats

Candesartan Inhibits LPS-induced Expression Increase of Toll-Like Receptor 4 and Downstream Inflammatory Factors Likely Via Angiotensin II Type 1 Receptor Independent Pathway in Human Renal Tubular Epithelial Cells.

Resveratrol pretreatment mitigates LPS-induced acute lung injury by regulating conventional dendritic cells' maturation and function